These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 12902452)

  • 1. Re: A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.
    Tu SM; Lin SH; Logothetis C
    J Natl Cancer Inst; 2003 Aug; 95(15):1174-5; author reply 1175. PubMed ID: 12902452
    [No Abstract]   [Full Text] [Related]  

  • 2. Re: A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.
    Atkins CD
    J Natl Cancer Inst; 2003 Feb; 95(4):332; author reply 333-4. PubMed ID: 12591994
    [No Abstract]   [Full Text] [Related]  

  • 3. Re: A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.
    Rosenthal M
    J Natl Cancer Inst; 2003 Feb; 95(4):332; author reply 333-4. PubMed ID: 12591992
    [No Abstract]   [Full Text] [Related]  

  • 4. Re: A Randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.
    Winquist E; Berry S
    J Natl Cancer Inst; 2004 Aug; 96(15):1183; author reply 1183-1184. PubMed ID: 15292391
    [No Abstract]   [Full Text] [Related]  

  • 5. Re: A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.
    Berruti A; Tucci M; Terrone C; Scarpa RM; Angeli A; Dogliotti L
    J Natl Cancer Inst; 2003 Feb; 95(4):332-3; author reply 333-4. PubMed ID: 12591993
    [No Abstract]   [Full Text] [Related]  

  • 6. Re: Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer.
    Grenader T; Shavit L; Uziely B; Peretz T
    J Natl Cancer Inst; 2005 Feb; 97(3):235-6. PubMed ID: 15687369
    [No Abstract]   [Full Text] [Related]  

  • 7. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.
    Saad F; Gleason DM; Murray R; Tchekmedyian S; Venner P; Lacombe L; Chin JL; Vinholes JJ; Goas JA; Chen B;
    J Natl Cancer Inst; 2002 Oct; 94(19):1458-68. PubMed ID: 12359855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bisphosphonates in prostate cancer: where are we and where should we go?
    Saad F
    J Natl Cancer Inst; 2003 Sep; 95(17):1262-3. PubMed ID: 12953073
    [No Abstract]   [Full Text] [Related]  

  • 9. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer.
    Saad F; Gleason DM; Murray R; Tchekmedyian S; Venner P; Lacombe L; Chin JL; Vinholes JJ; Goas JA; Zheng M;
    J Natl Cancer Inst; 2004 Jun; 96(11):879-82. PubMed ID: 15173273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Re: Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer.
    Parker CC
    J Natl Cancer Inst; 2004 Oct; 96(19):1480; author reply 1480-1. PubMed ID: 15467039
    [No Abstract]   [Full Text] [Related]  

  • 11. The use of bisphosphonates in prostate cancer.
    Khan MA
    BJU Int; 2003 Jul; 92(1):152. PubMed ID: 12823405
    [No Abstract]   [Full Text] [Related]  

  • 12. Clinical trials test bisphosphonates in hormone-sensitive prostate cancer.
    Bankhead C
    J Natl Cancer Inst; 2003 Sep; 95(17):1273-4. PubMed ID: 12953081
    [No Abstract]   [Full Text] [Related]  

  • 13. Zoledronic acid significantly reduces pathologic fractures in patients with advanced-stage prostate cancer metastatic to bone.
    Saad F
    Clin Prostate Cancer; 2002 Dec; 1(3):145-52. PubMed ID: 15046689
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of bisphosphonates in hormone-refractory prostate cancer.
    Saad F; Karakiewicz P; Perrotte P
    World J Urol; 2005 Feb; 23(1):14-8. PubMed ID: 15666171
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances in prevention and treatment of bone metastases in prostate cancer. Role of RANK/RANKL inhibition.
    Gomez-Veiga F; Ponce-Reixa J; Martinez-Breijo S; Planas J; Morote J
    Actas Urol Esp; 2013 May; 37(5):292-304. PubMed ID: 23246105
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of bisphosphonates in the management of skeletal complications of bone metastases and selection of clinical endpoints.
    Major PP; Cook R
    Am J Clin Oncol; 2002 Dec; 25(6 Suppl 1):S10-8. PubMed ID: 12562046
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The effect of bisphosphonates on bone metastasis of hormone-refractory prostate cancer].
    Tanaka T; Kawashima H; Kuratsukuri K; Sugimura K; Nakatani T
    Hinyokika Kiyo; 2006 Jun; 52(6):491-4. PubMed ID: 16848364
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Zoledronic acid: a new advance in managing skeletal events in prostate cancer.
    Kirby RS
    BJU Int; 2003 Apr; 91(6):464-5. PubMed ID: 12656892
    [No Abstract]   [Full Text] [Related]  

  • 19. Treatment of bone complications in advanced prostate cancer: rationale for bisphosphonate use and results of a phase III trial with zoledronic acid.
    Saad F
    Semin Oncol; 2002 Dec; 29(6 Suppl 21):19-27. PubMed ID: 12584691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Use of zoledronic acid for high risk prostate cancer patients].
    Rexer H
    Urologe A; 2005 Feb; 44(2):183-4. PubMed ID: 15793897
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.